Fuji Yakuhin Co., Ltd.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Saitama Japan (1930)

Organization Overview

First Clinical Trial
2013
NCT02348307
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Fuji Yakuhin Co., Ltd.

Active Ingredients

Drugs in Phase 3 Trials (4)

benzbromarone (1 trial)

dotinurad (Urece) (16 trials)

febuxostat (uloric) (1 trial)

inulin (1 trial)

Drugs in Phase 2 Trials (2)

moxifloxacin (avelox) (1 trial)

Topiroxostat (2 trials)

Drugs in Phase 1 Trials (1)

oxaprozin (daypro) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetic Nephropathies (Phase 2)

Gout (Phase 3)

Hepatic Insufficiency (Phase 1)

Hyperuricemia (Phase 3)

Kidney Diseases (Phase 3)

Liver Failure (Phase 1)

Renal Insufficiency (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 18
  • # of Trial APIs: 7